Literature DB >> 17762156

Differential effects of an anti-oxidant intervention on cardiomyocyte expression of adrenomedullin and intermedin and their receptor components in chronic nitric oxide deficiency.

David Bell1, YouYou Zhao, Francis P G McCoy, Adrian B Devine, Barbara J McDermott.   

Abstract

BACKGROUND: Chronic inhibition of nitric oxide (NO) synthesis is associated with hypertension, myocardial oxidative stress and hypertrophic remodeling. Up-regulation of the cardiomyocyte adrenomedullin (AM) / intermedin (IMD) receptor signaling cascade is also apparent in NO-deficient cardiomyocytes: augmented expression of AM and receptor activity modifying proteins RAMP2 and RAMP3 is prevented by blood pressure normalization while that of RAMP1 and intermedin (IMD) is not, indicating that the latter is regulated by a pressure-independent mechanism. AIMS: to verify the ability of an anti-oxidant intervention to normalize cardiomyocyte oxidant status and to investigate the influence of such an intervention on expression of AM, IMD and their receptor components in NO-deficient cardiomyocytes.
METHODS: NO synthesis inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME, 35 mg/kg/day) was given to rats for 8 weeks, with/without con-current administration of antioxidants (Vitamin C (25mg/kg/day) and Tempol (25mg/kg/day)).
RESULTS: In left ventricular cardiomyocytes isolated from L-NAME treated rats, increased oxidative stress was indicated by augmented (3.6 fold) membrane protein oxidation, enhanced expression of catalytic and regulatory subunits of pro-oxidant NADPH oxidases (NOX1, NOX2) and compensatory increases in expression of anti-oxidant glutathione peroxidase and Cu/Zn superoxide dismutases (SOD1, SOD3). Vitamin C plus Tempol did not reduce systolic blood pressure but normalized augmented plasma levels of IMD, but not of AM, and in cardiomyocytes: (i) abolished increased membrane protein oxidation; (ii) normalized augmented expression of prepro-IMD and RAMP1, but not prepro-AM, RAMP2 and RAMP3; (iii) attenuated (by 42%) increased width and normalized expression of hypertrophic markers, skeletal-alpha-actin and prepro-endothelin-1 similarly to blood pressure normalization but in contrast to blood pressure normalization did not attenuate augmented brain natriuretic peptide (BNP) expression.
CONCLUSION: normalization specifically of augmented IMD/RAMP1 expression in NO-deficient cardiomyocytes by antioxidant intervention in the absence of blood pressure reduction indicates that these genes are likely to be induced directly by myocardial oxidative stress. Although oxidative stress contributed to cardiomyocyte hypertrophy, induction of IMD and RAMP1 is unlikely to be secondary to cardiomyocyte hypertrophy. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762156     DOI: 10.1159/000107513

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  9 in total

1.  Rat intermedin1-47 does not improve functional recovery in postischemic hearts.

Authors:  Gerald Münzel; Alexander Schlier; Rolf Schreckenberg; Yaser Abdallah; Klaus-Dieter Schlüter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-01       Impact factor: 3.000

2.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

3.  Endothelin activation of reactive oxygen species mediates stress-induced pressor response in Dahl salt-sensitive prehypertensive rats.

Authors:  Gerard D'Angelo; Analia S Loria; David M Pollock; Jennifer S Pollock
Journal:  Hypertension       Date:  2010-06-14       Impact factor: 10.190

Review 4.  Effects of tempol and redox-cycling nitroxides in models of oxidative stress.

Authors:  Christopher S Wilcox
Journal:  Pharmacol Ther       Date:  2010-02-11       Impact factor: 12.310

5.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

Review 6.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 7.  Chemistry and antihypertensive effects of tempol and other nitroxides.

Authors:  Christopher S Wilcox; Adam Pearlman
Journal:  Pharmacol Rev       Date:  2008-12       Impact factor: 25.468

8.  Prognostic Value of Plasma Intermedin Level in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.

Authors:  Pengyang Li; Lin Shi; Yalei Han; Yuntao Zhao; Yongfen Qi; Bin Wang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

9.  Intermedin1-53 attenuates atherosclerotic plaque vulnerability by inhibiting CHOP-mediated apoptosis and inflammasome in macrophages.

Authors:  Jin-Ling Ren; Yao Chen; Lin-Shuang Zhang; Ya-Rong Zhang; Shi-Meng Liu; Yan-Rong Yu; Mo-Zhi Jia; Chao-Shu Tang; Yong-Fen Qi; Wei-Wei Lu
Journal:  Cell Death Dis       Date:  2021-05-01       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.